Trial Site News
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
  • Register
  • Log In
  • News
  • Video
  • Podcast
  • More
Trial Site News
  • News For You
  • Op-Eds
  • Video
  • Podcasts
  • Investor Watch
  • Write for us
  • News for You
  • Op-Eds
  • Video
  • Podcasts
  • Covid-19
  • Investor Watch

Topic: Neurology

PaxMedica Announces Efficacy of PAX-101 (IV suramin) in Reducing Core Symptoms of Autism Spectrum Disorder

PaxMedica announced positive results from a phase 2 dose-ranging clinical trial evaluating PAX-124890-=101 demonstrated sustained improvements over placebo in the […]

PaxMedica Announces Efficacy of PAX-101 (IV suramin) in Reducing Core Symptoms of Autism Spectrum Disorder
3 weeks ago
Share

AC Immune Announces Positive Interim Data from Phase 1b/2a Trial of Alzheimer’s Disease Vaccine

AC Immune SA announced positive interim results from its ongoing Phase 1b/2a clinical trial evaluating its first-in-class anti-phospho-Tau (pTau) vaccine […]

AC Immune Announces Positive Interim Data from Phase 1b2a Trial of Alzheimer’s Disease Vaccine
3 weeks ago
Share

Mesoblast Phase 3 Data Reveals a Single Injection of Rexlemestrocel-L Results in 2+ Years Pain Reduction, Opioid Sparing in Patients with Chronic Low Back Pain Due to Degenerative Disc Disease

Mesoblast announced results from a Phase 3 trial of its allogeneic mesenchymal precursor cell (MPC) therapy rexlemestrocel-L in patients with […]

Mesoblast Phase 3 Data Reveals a Single Injection of Rexlemestrocel-L Results in 2+ Years Pain Reduction, Opioid Sparing in Patients with Chronic Low Back Pain Due to Degenerative Disc Disease
4 weeks ago
Share

Concert Pharma’s Adjunctive Schizophrenia Treatment, CTP-692, Fails to Meet Phase 2 Endpoints

Concert Pharmaceuticals reported that its Phase 2 trial to evaluate CTP-692 as an adjunctive treatment in patients with schizophrenia did […]

Concert Pharma’s Adjunctive Schizophrenia Treatment, CTP-692, Fails to Meet Phase 2 Endpoints
1 month ago
Share

Biogen Discontinues Development of Parkinson’s Drug Following Disappointing Phase 2 Data

Biogen announced in its annual results and earnings presentation that its Phase II SPARK study of cinpanemab (BIIB054), under development for Parkinson’s […]

Biogen Discontinues Development of Parkinson’s Drug Following Disappointing Phase 2 Data
1 month ago
Share

BioHaven’s Troriluzole Fails Co-Primary Endpoints in Phase 2 Trial for Mild-to-Moderate Alzheimer’s Disease

BioHaven Pharmaceuticals announced the outcome from a focused analysis of the topline co-primary and key secondary data from its Phase […]

BioHaven’s Troriluzole Fails Co-Primary Endpoints in Phase 2 Trial for Mild-to-Moderate Alzheimer's Disease
1 month ago
Share

University of Buffalo Investigator Receives $3.1m from NIH to Investigate Impact of DBS on Parkinson’s Patients

Patients with Parkinson’s disease who are treated with deep brain stimulation (DBS) generally have unpredictable and varied speech outcomes after […]

University of Buffalo Investigator Receives $3.1m from NIH to Investigate Impact of DBS on Parkinson’s Patients
2 months ago
Share

DOD-backed Research Indicates COVID-19 Lasting Symptoms Not Neurological but Result from Small Blood Cells

The Uniformed Services University and the National Institutes of Health led a study with eyebrow raising results: that the cause […]

DOD-backed Research Indicates COVID-19 Lasting Symptoms Not Neurological but Result from Small Blood Cells
2 months ago
Share

Lilly’s Phase 2 TRAILBLAZER-ALZ Study Shows Donanemab Slows Clinical Decline of Alzheimer’s Disease

Eli Lilly reported positive results from its Phase II TRAILBLAZER-ALZ trial, which showed treatment with donanemab resulted in significant slowing […]

Lilly’s Phase 2 TRAILBLAZER-ALZ Study Shows Donanemab Slows Clinical Decline of Alzheimer's Disease
2 months ago
Share

NIH Researchers Find COVID-19 Triggered Brain Damage not by Infection but via Blood Vessel Damage & Inflammation

Could it be that COVID-19 impacts the brain via microvascular blood vessel damage but not by direct viral infection? That’s the […]

NIH Researchers Find COVID-19 Triggered Brain Damage not by Infection but via Blood Vessel Damage & Inflammation
2 months ago
Share

Posts navigation

Older posts

Latest Podcasts

Alan Cannell talks COVID-19: Nobody Likes Cheap Solutions | Podcast S2 E41

Dr. Pierre Kory Talks Covid-19, Ivermectin and the FLCCC | Podcast E43

An Interview With Patricia Carter: Patient Engagement and Retention in Clinical Trials

Dr. Negin Hajizadeh: Researchers Finding A Very Effective Treatment For Covid-19 In New Study

Dr. Jean-Jacques Rajter and Dr. Juliana Cepelowicz Rajter Discuss Ivermectin In Broward County | Podcast S2 E 27

159 W Broadway, Suite 200
Salt Lake City, UT 84101

[email protected]

Connect With Us

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

© 2021 TRIALSITE NEWS. ALL RIGHTS RESERVED.